OIG Issues Semiannual Report to Congress
Conclusion
As written in a January 2017 article in Life Science Compliance Update, it is too soon to tell the effect the Trump Administration will have on the pharmaceutical industry. This report and the recommendations contained therein highlight some of the focuses of OIG, but those have the propensity to change, depending on the incoming Administration.
Related Stories21st Century Bill Headed to President Obama’s DeskLeahy, Wyden Send Letter to DOJ Regarding DEA Enforcement ActionsAHR Holds Congressional Briefing Focused on Cost Growth
Source: Policy and Medicine - Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
More News: American Health | Cardiology | Congestive Heart Failure | Disability | Health Management | Health Medicine & Bioethics Commentators | Heart | Heart Failure | Insulin | Lawsuits | Legislation | Medicaid | Medicare | Nurses | Nursing | Obama | Politics | Science | Substance Abuse